{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:47Z","timestamp":1790806847893,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ophtha.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T09:23:38Z","timestamp":1528363418000},"page":"1961-1966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["A Dosing Study of Bevacizumab for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"125","author":[{"given":"David K.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevano W.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-0085","authenticated-orcid":false,"given":"Lingkun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Baker","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine O.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-5465","authenticated-orcid":false,"given":"Iason S.","family":"Mantagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-8230","authenticated-orcid":false,"given":"Raymond T.","family":"Kraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.05.001_bib1","first-page":"227","article-title":"Childhood blindness in the context of vision 2020\u2013the right to sight","volume":"79","author":"Gilbert","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ophtha.2018.05.001_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.05.001_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib5","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"9","author":"Arambulo","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2018.05.001_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2018.05.001_bib10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","article-title":"Anti-vascular endothelial growth factor and retinopathy of prematurity","volume":"92","author":"Sears","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2018.05.001_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.05.001_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome\u2013structure and function. Cryotherapy for retinopathy of prematurity cooperative group","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.05.001_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"key":"10.1016\/j.ophtha.2018.05.001_bib20","first-page":"137","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2018.05.001_bib21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.05.001_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2018.05.001_bib23","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.05.001_bib24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.05.001_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1167\/iovs.13-13429","article-title":"Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.05.001_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.05.001_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: A randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ophtha.2018.05.001_bib28","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018304913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T03:11:36Z","timestamp":1542337896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018304913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0161642018304913"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733432570.793554955","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Dosing Study of Bevacizumab for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}